HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis
USA - NASDAQ:HRMY - US4131971040 - Common Stock
29.71 USD
-1.01 (-3.29%)
HRMY gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HRMY could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
HRMY had positive earnings in 4 of the past 5 years.
HRMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HRMY has a better Return On Assets (16.33%) than 95.83% of its industry peers.
With an excellent Return On Equity value of 23.40%, HRMY belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
HRMY has a better Return On Invested Capital (17.95%) than 94.79% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HRMY is above the industry average of 15.46%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.33% | ||
| ROE | 23.4% | ||
| ROIC | 17.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
Looking at the Profit Margin, with a value of 23.42%, HRMY belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
In the last couple of years the Profit Margin of HRMY has grown nicely.
With an excellent Operating Margin value of 28.72%, HRMY belongs to the best of the industry, outperforming 93.75% of the companies in the same industry.
HRMY's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 78.34%, HRMY belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.72% | ||
| PM (TTM) | 23.42% | ||
| GM | 78.34% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
HRMY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
HRMY has a better debt/assets ratio than last year.
2.2 Solvency
HRMY has an Altman-Z score of 5.19. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.19, HRMY is in the better half of the industry, outperforming 77.60% of the companies in the same industry.
The Debt to FCF ratio of HRMY is 0.67, which is an excellent value as it means it would take HRMY, only 0.67 years of fcf income to pay off all of its debts.
HRMY has a better Debt to FCF ratio (0.67) than 95.83% of its industry peers.
HRMY has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
HRMY has a Debt to Equity ratio of 0.20. This is comparable to the rest of the industry: HRMY outperforms 45.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.67 | ||
| Altman-Z | 5.19 |
ROIC/WACC1.98
WACC9.05%
2.3 Liquidity
A Current Ratio of 3.84 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a Current ratio of 3.84. This is in the better half of the industry: HRMY outperforms 61.98% of its industry peers.
A Quick Ratio of 3.80 indicates that HRMY has no problem at all paying its short term obligations.
HRMY's Quick ratio of 3.80 is fine compared to the rest of the industry. HRMY outperforms 63.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.71% over the past year.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
Looking at the last year, HRMY shows a very strong growth in Revenue. The Revenue has grown by 22.80%.
The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)22.8%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.72%
3.2 Future
The Earnings Per Share is expected to grow by 34.90% on average over the next years. This is a very strong growth
Based on estimates for the next years, HRMY will show a quite strong growth in Revenue. The Revenue will grow by 14.35% on average per year.
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.34, the valuation of HRMY can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 90.10% of the companies listed in the same industry.
HRMY is valuated cheaply when we compare the Price/Earnings ratio to 26.03, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 7.20, the valuation of HRMY can be described as very cheap.
HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 90.63% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.27, HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 7.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
93.23% of the companies in the same industry are more expensive than HRMY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.61 | ||
| EV/EBITDA | 5.51 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
HRMY's earnings are expected to grow with 27.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y28.23%
EPS Next 3Y27.97%
5. Dividend
5.1 Amount
HRMY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HRMY (11/5/2025, 10:06:03 AM)
29.71
-1.01 (-3.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.62%
Inst Owner Change0.01%
Ins Owners0.52%
Ins Owner Change-61.56%
Market Cap1.71B
Revenue(TTM)714.73M
Net Income(TTM)180.90M
Analysts78.82
Price Target44.88 (51.06%)
Short Float %7.36%
Short Ratio4.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.92%
Min EPS beat(2)-11.17%
Max EPS beat(2)31%
EPS beat(4)3
Avg EPS beat(4)12.28%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)59.09%
EPS beat(12)9
Avg EPS beat(12)123.49%
EPS beat(16)11
Avg EPS beat(16)86.61%
Revenue beat(2)0
Avg Revenue beat(2)-2.22%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-0.9%
Revenue beat(12)3
Avg Revenue beat(12)-1.17%
Revenue beat(16)4
Avg Revenue beat(16)-1.05%
PT rev (1m)-13.11%
PT rev (3m)-11.47%
EPS NQ rev (1m)4.51%
EPS NQ rev (3m)-5.54%
EPS NY rev (1m)1.17%
EPS NY rev (3m)-4.07%
Revenue NQ rev (1m)1.9%
Revenue NQ rev (3m)2.24%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)-0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.34 | ||
| Fwd PE | 7.2 | ||
| P/S | 2.21 | ||
| P/FCF | 6.61 | ||
| P/OCF | 6.6 | ||
| P/B | 2.21 | ||
| P/tB | 2.54 | ||
| EV/EBITDA | 5.51 |
EPS(TTM)3.18
EY10.7%
EPS(NY)4.13
Fwd EY13.89%
FCF(TTM)4.49
FCFY15.12%
OCF(TTM)4.5
OCFY15.16%
SpS13.43
BVpS13.44
TBVpS11.68
PEG (NY)0.31
PEG (5Y)N/A
Graham Number31.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.33% | ||
| ROE | 23.4% | ||
| ROCE | 23.91% | ||
| ROIC | 17.95% | ||
| ROICexc | 45.94% | ||
| ROICexgc | 63.76% | ||
| OM | 28.72% | ||
| PM (TTM) | 23.42% | ||
| GM | 78.34% | ||
| FCFM | 33.46% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.67 | ||
| Debt/EBITDA | 0.62 | ||
| Cap/Depr | 2.7% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 13.83 | ||
| Cash Conversion | 105.45% | ||
| Profit Quality | 142.89% | ||
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.8 | ||
| Altman-Z | 5.19 |
F-Score6
WACC9.05%
ROIC/WACC1.98
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue 1Y (TTM)22.8%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.72%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
EBIT growth 1Y13.95%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year36.94%
EBIT Next 3Y27.36%
EBIT Next 5Y22.83%
FCF growth 1Y60.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.46%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 9.34 and the Price/Book (PB) ratio is 2.21.